ANSTO Publications Online >
Journal Publications >
Journal Articles >

Please use this identifier to cite or link to this item: http://apo.ansto.gov.au/dspace/handle/10238/2848

Title: Technology evaluation: huN901-DM1 (ImmunoGen).
Authors: Smith, SV
Keywords: Evaluation
Neoplasms
Lungs
Commercialization
Drugs
Antibodies
Issue Date: 25-Jul-2005
Publisher: Thomson Reuters
Citation: Smith, S. V. (2005). Technology evaluation: huN901-DM1 (ImmunoGen). Current Opinion in Molecular Therapeutics, 7(4), 394-402.
Abstract: ImmunoGen is developing huN901-DMI, a compound comprised of a CD56-targeted humanized N901 antibody conjugated to the company's proprietary cytotoxic agent. DM1, using its tumor-activated prodrug technology, for the potential treatment of cancers that express CD56, in particular, small-cell lung cancer. © 2005, Thomson Reuters
URI: http://www.biomedcentral.com/content/pdf/cd-614041.pdf
http://apo.ansto.gov.au/dspace/handle/10238/2848
ISSN: 1464-8431
Appears in Collections:Journal Articles

Files in This Item:

There are no files associated with this item.

Items in APO are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback